Rdy Limited

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India. The company has three departments: Global generics, Pharmaceutical Services and Active Ingredients (PSAI) and specialty products. The global generic medicine sector produces and sells finished medicines as brand formulas or generic medicine doses. This department also engages in biological agent business. The PSAI department develops Active Pharmaceutical Ingredients (API) and intermediate substances as the main components of finished medicine products. This department also provides contract research services to other companies; and manufactures and sells APIs and steroids according to the specific requirements of customers. The specialty product department focuses on the discovery, development, and commercialization of new small-molecule drugs in therapeutic areas such as anti-infectives, metabolic disorders, and pain and inflammation. The department also provides differentiated product formulas for medical needs; and a series of patented dermatology products within the permit. As of March 31, 2015, this department had 18 active products in the patented product development process, which were at different stages of development. The company's treatment programs mainly include gastrointestinal, cardiovascular, pain management, oncology, dermatology, urology and nephrology. The company has established a strategic partnership with GlaxoSmithKline plc to develop and sell products outside India; with Curis, Inc. to discover, develop and commercialize small molecule antagonists for immuno-oncology and precision oncology; and signed a cooperation agreement with Merck Serono to jointly develop a series of biosimilar compounds in oncology, mainly focusing on monoclonal antibodies.